Wendy Cleare

Characterization of a Murine Monoclonal Antibody to<i>Cryptococcus neoformans</i>Polysaccharide That Is a Candidate for Human Therapeutic Studies

Arturo Casadevall, Wendy Cleare, Marta Feldmesser et al. · Antimicrobial Agents and Chemotherapy · 1998 · 303 citations · Full text

Epitope Location in the <i>Cryptococcus neoformans</i> Capsule Is a Determinant of Antibody Efficacy

Gabriel Nussbaum, Wendy Cleare, Arturo Casadevall et al. · The Journal of Experimental Medicine · 1997 · 100 citations · Full text

Mabs 12A1, Immunocytochemical Technique, Microbial Pathogens +21

Effects of Voriconazole on <i>Cryptococcus neoformans</i>

David van Duin, Wendy Cleare, Óscar Zaragoza et al. · Antimicrobial Agents and Chemotherapy · 2004 · 77 citations · Full text

Antifungal Agent, Broad-spectrum Triazole, Antibiotics +13

Amphotericin B and Fluconazole Affect Cellular Charge, Macrophage Phagocytosis, and Cellular Morphology of<i>Cryptococcus neoformans</i>at Subinhibitory Concentrations

Joshua D. Nosanchuk, Wendy Cleare, Sarah P. Franzot et al. · Antimicrobial Agents and Chemotherapy · 1999 · 64 citations · Full text

The Different Binding Patterns of Two Immunoglobulin M Monoclonal Antibodies to<i>Cryptococcus neoformans</i>Serotype A and D Strains Correlate with Serotype Classification and Differences in Functional Assays

Wendy Cleare, Arturo Casadevall · Clinical and Diagnostic Laboratory Immunology · 1998 · 49 citations · Full text

Mabs 12A1, Pathogen Detection, Pathology +17